Bionano Genomics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
BNGO$1.23+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-inCapital | AccumulatedDeficit | AccumulatedOtherComprehensiveIncome (Loss) | TotalStockholders’Equity | |
| Balance at January 1, 2024 | 762,600 | $— | $677,342,000 | $(581,208,000) | $23,000 | $96,157,000 |
| Stock-based compensation expense | — | — | 9,736,000 | — | — | 9,736,000 |
| Issue common stock and warrants, net of issuance costs | 968,600 | — | 41,481,000 | — | — | 41,481,000 |
| Issue stock for warrant exercises | 133,500 | — | 4,000 | — | — | 4,000 |
| Issue stock for employee stock purchase plan | 500 | — | 13,000 | — | — | 13,000 |
| Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes | 200 | — | (3,000) | — | — | (3,000) |
| Net loss | — | — | — | (112,017,000) | — | (112,017,000) |
| Other comprehensive income | — | — | — | — | 4,000 | 4,000 |
| Balance at December 31, 2024 | 1,865,400 | $— | $728,573,000 | $(693,225,000) | $27,000 | $35,375,000 |
| Stock-based compensation expense | — | — | 4,534,000 | — | — | 4,534,000 |
| Issue common stock and warrants, net of issuance costs | 8,496,600 | 1,000 | 30,559,000 | — | — | 30,560,000 |
| Issue stock for warrant exercises | 355,000 | — | 9,000 | — | — | 9,000 |
| Issuance of common stock for convertible debentures payable | 22,000 | — | 350,000 | — | — | 350,000 |
| Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes | 1,200 | — | 1,000 | — | — | 1,000 |
| Net loss | — | — | — | (26,395,000) | — | (26,395,000) |
| Other comprehensive income | — | — | — | — | (10,000) | (10,000) |
| Balance at December 31, 2025 | 10,740,200 | $1,000 | $764,026,000 | $(719,620,000) | $17,000 | $44,424,000 |
BIONANO GENOMICS, INC
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.